COVID-19EFRUPICNCT05074927
Pulmonary Function in Patients Recovering From COVID19 Infection : a Pilot Study
A study testing diaphragm ultrasonography in people with COVID-19, run by University Hospital, Limoges at 2 sites in France.
Trial summary
The current state of knowledge shows the presence of respiratory sequelae after acute infection with COVID-19 and the importance of these long-term respiratory dysfunctions have to be determined. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19
- What is being tested?
- diaphragm ultrasonography
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 2 sitesFrance
- Study dates
- 31 Jan 2022to 13 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- SARS-CoV-2 infection proven by RT-PCR.
- Patient hospitalised for the management of SARS-CoV-2 infection and included 3 months after the end of his hospitalisation at the CHU of Limoges.
- Patient of legal age.
- Patient affiliated to a social security regime.
- Patient having given informed consent
Who cannot join
- Known pregnancy.
- Patients who are contraindicated to perform the 6-minute walk test.
- Patients unable to understand or adhere to the protocol.
- Patients deprived of liberty.
- Patients under court order, tutorship or curatorship.
- Minor patients
Trial locations and contacts
2 sites in 1 country.
About this study
The current state of knowledge shows the presence of respiratory sequelae after acute infection with COVID-19 and the importance of these long-term respiratory dysfunctions have to be determined.
Aim of our study is describe diaphragmatic amplitude using diaphragm ultrasonography in patients recovering from SARS-CoV-2 pneumonia at 3 and 6 months after the acute episode.
Read the detailed description
patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) will be included to follow the impact of severe acute respiratory syndrom coronavirus 2 on pulmonary function, diaphragm function and exercice capacity. Surviving patients will be evaluated at 3 and 6 months after hospital discharge. The assesment will include diaphragm ultrasonography, spirometry (FEV1,FVC), carbon monoxide transfert (TLCO adjusted for haemoglobin), inspiratory an expiratory respiratory muscle strength (Pimax and Pemax) and 6 minutes walk distance (6MWD).The main outcome will be diaphragm excursion assessed by ultrasound.
- Conditions
- COVID-19
- Being tested
- diaphragm ultrasonography
- Keywords
- Lung function, Diaphragm ultrasonography, Chronic Inflammatory Rheumatism
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
diaphragm ultrasonographyDiagnostic test
For all patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) : diaphragm ultrasonography at 3 (M0) and 6 months (M3) after the end of his hospitalisation
| Study group | Role | What they receive |
|---|---|---|
| Cohort | Other | All patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) Receives: Diagnostic Test: diaphragm ultrasonography |
What is being measured
The primary outcome is the main question the study is designed to answer.
The change diaphragmatic amplitude using diaphragm ultrasonography in patients recovering from SARS-CoV-2 pneumonia.
Diaphragmatic amplitude assessed by ultrasound at M0 and M3.
Measured: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
Secondary outcomes (8)
the correlation between the values of diaphragmatic travel and Pi max and Pe max at M0 and M3.
Diaphragmatic amplitude, PI max and PE max
Measured: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
the difference in diaphragmatic amplitude between M0 and M3.
Diaphragmatic amplitude at M0 and M3
Measured: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
the difference in FEV1 between M0 and M3.
FEV1 at M0 and M3.
Measured: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
the difference in FVC between M0 and M3.
FVC at M0 and M3.
Measured: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
the difference in DLCO between M0 and M3.
DLCO at M0 and M3.
Measured: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
the difference in Pi max and Pe max between M0 and M3.
PI max and PE max at M0 and M3
Measured: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
dyspnoea between M0 and M3.
mMRC dyspnoea scale at M0 and M3.
Measured: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
the functional capacity between M0 and M3.
6-minutes walk test distance at M0 and M3.
Measured: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Oct 2021
- Study start31 Jan 2022
- Primary completion13 Jul 2023
- Study completion13 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- More trials run by University Hospital, LimogesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Limoges
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- VINCENT François, Pr, Principal investigator, CHU Limoges
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05074927
- Sponsor's protocol ID
- 87RI20_0073
- Acronym
- EFRUPIC
- Status last verified
- Jun 2026
- First submitted
- 30 Sep 2021
- Last updated
- 26 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pulmonary Function in Patients Recovering From COVID19 Infection : a Pilot Study
- ClinicalTrials.gov ID
- NCT05074927
- Acronym / sponsor ID
- EFRUPIC / 87RI20_0073
- Conditions
- COVID-19
- Keywords
- Lung function, Diaphragm ultrasonography, Chronic Inflammatory Rheumatism
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 24 participants (actual)
- Lead sponsor
- University Hospital, LimogesUniversity, hospital or other
- Study start
- 31 Jan 2022 (actual)
- Primary completion
- 13 Jul 2023 (actual)
- Study completion
- 13 Jul 2026 (estimated)
- First posted
- 12 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The current state of knowledge shows the presence of respiratory sequelae after acute infection with COVID-19 and the importance of these long-term respiratory dysfunctions have to be determined.
Aim of our study is describe diaphragmatic amplitude using diaphragm ultrasonography in patients recovering from SARS-CoV-2 pneumonia at 3 and 6 months after the acute episode.
Detailed description
patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) will be included to follow the impact of severe acute respiratory syndrom coronavirus 2 on pulmonary function, diaphragm function and exercice capacity. Surviving patients will be evaluated at 3 and 6 months after hospital discharge. The assesment will include diaphragm ultrasonography, spirometry (FEV1,FVC), carbon monoxide transfert (TLCO adjusted for haemoglobin), inspiratory an expiratory respiratory muscle strength (Pimax and Pemax) and 6 minutes walk distance (6MWD).The main outcome will be diaphragm excursion assessed by ultrasound.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cohort | Other | Diagnostic Test: diaphragm ultrasonographyAll patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- SARS-CoV-2 infection proven by RT-PCR.
- Patient hospitalised for the management of SARS-CoV-2 infection and included 3 months after the end of his hospitalisation at the CHU of Limoges.
- Patient of legal age.
- Patient affiliated to a social security regime.
- Patient having given informed consent
Key exclusion criteria (6 listed)
- Known pregnancy.
- Patients who are contraindicated to perform the 6-minute walk test.
- Patients unable to understand or adhere to the protocol.
- Patients deprived of liberty.
- Patients under court order, tutorship or curatorship.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| diaphragm ultrasonographyFor all patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) : diaphragm ultrasonography at 3 (M0) and 6 months (M3) after the end of his hospitalisation | Diagnostic test | Cohort |
Primary outcome
The change diaphragmatic amplitude using diaphragm ultrasonography in patients recovering from SARS-CoV-2 pneumonia.
Time frame: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
Diaphragmatic amplitude assessed by ultrasound at M0 and M3.
8 secondary outcomes
the correlation between the values of diaphragmatic travel and Pi max and Pe max at M0 and M3.
Time frame: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
the difference in diaphragmatic amplitude between M0 and M3.
Time frame: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
the difference in FEV1 between M0 and M3.
Time frame: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
the difference in FVC between M0 and M3.
Time frame: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
the difference in DLCO between M0 and M3.
Time frame: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
the difference in Pi max and Pe max between M0 and M3.
Time frame: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
dyspnoea between M0 and M3.
Time frame: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
the functional capacity between M0 and M3.
Time frame: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2026.
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
VINCENT François, Pr principal investigator
CHU Limoges
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing diaphragm ultrasonography in people with COVID-19, run by University Hospital, Limoges at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The change diaphragmatic amplitude using diaphragm ultrasonography in patients recovering from SARS-CoV-2 pneumonia. (time frame: at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2026.